Inc., a platform nanotechnology company developing technologies for a number
of diverse fields ranging from medical diagnostics to solar cell concentrators,
announced that Heiner Dreismann, Ph.D., has joined the company's Board of Directors
and will chair Shrink's Business Advisory Board.
Dr. Dreismann is the former Chief Executive Officer of Roche Molecular Diagnostics
(Roche), a division of F. Hoffmann-La Roche.
Shrink CEO Mark L. Baum said, "Dr. Dreismann is one of the top industry
experts in the field of molecular and medical diagnostics. He has a proven track-record
of leadership in the development, commercialization and adoption of diagnostics,
and brings valuable real-world experience as we begin integrating our breakthrough
metal-enhanced fluorescence technologies into diagnostics and other life sciences
products that can make a difference in people's lives. Dr. Dreismann, throughout
his impressive career and consistent successful track record, has developed
numerous domestic and international industry contacts which we believe will
open doors for our company. We are very pleased to welcome Dr. Dreismann to
Shrink and look forward to his active participation and contribution to our
The company noted that Roche pioneered the clinical implementation of molecular
diagnostics. While at Roche, Dr. Dreismann led the introduction in Europe of
the company's PCR (polymerase chain reaction) and, now industry-standard, real-time
PCR-based tests. PCR is a Nobel-prize winning technology which has been recognized
as one of the most important scientific developments of our generation. PCR
allows scientists to copy a single segment of DNA billions of times, making
it possible to take a specimen, copy its genetic sequence, and, within hours,
generate a test sample sufficient to perform a detailed analysis of a specific
Under Dr. Dreismann's leadership as Chief Executive Officer, leading a team
of more than 1,500 professionals, Roche evolved into one of the world's leading
molecular diagnostics companies with annual sales to over US $1.2 billion and
the significant expansion of their portfolio of diagnostic tests and hardware.
Prior to his appointment as Chief Executive Officer, Dr. Dreismann held other
senior positions within Roche in the areas of Global Business Development, Business
Unit Manager for PCR and Microbiology, as well as R&D positions in microbiology
and infectious diseases and in manufacturing.